A Prospective Five-Year Follow-up After peg-Interferon Plus Nucleotide Analogue Treatment or no Treatment in HBeAg Negative Chronic Hepatitis B Patients.
J Clin Exp Hepatol
; 12(3): 735-744, 2022.
Article
em En
| MEDLINE
| ID: mdl-35677522
ADV, Adefovir dipivoxil; ALT, Alanine aminotransferase; CHB, Chronic hepatitis B; EOT, End of treatment; GZ, Grey zone; HBeAg, Hepatitis B e antigen; HBsAg, Hepatitis B surface antigen; HCC, Hepatocellular Carcinoma; HNCH, HBeAg-negative chronic infection; NA, Nucleot(s)ide analogue; ROC, Receiver operating characteristic; TAF, Tenofovir alafenamide fumarateor; TDF, Tenofovir disoproxil fumarate; ULN, Upper limit of normal; UMC, University Medical Centers; combination therapy; functional cure; hepatitis B virus; inactive carrier; low viral load; peg-IFN, Pegylated-interferon
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Tipo de estudo:
Clinical_trials
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article